Targeting CD39 as a Therapeutic for Cancer Immunotherapy
Expert Reviews in Molecular Medicine · 2026 · 28
DOI: 10.1017/erm.2026.10033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Reviews in Molecular Medicine, online erschienen am 26.01.2026. Verfasst von Zhongliang Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Faculty of Health Sciences, https://ror.org/01r4q9n85University of Macau, Avenida da Universidade, Taipa, Macao an…. Hauptthemen laut MEDLINE: Apyrase, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundo para o Desenvolvimento das Ciências e da Tecnologia, National Natural Science Foundation of China.
Abstract (Originalsprache)
CD39 plays a pivotal role in the ATP-to-adenosine signalling pathway, serving as a critical mediator of immune suppression within the tumour microenvironment. Increasing preclinical evidence indicates that its inhibition can restore antitumour immunity and improve the efficacy of established treatments. In this review, we summarise the biology of CD39, its role in shaping the immunosuppressive tumour microenvironment, and therapeutic strategies currently under development. We also discuss early clinical progress and safety considerations, along with major challenges and future perspectives. Targeting CD39 represents a promising strategy to overcome tumour-induced immunosuppression and ongoing advances in therapeutic development could usher in next-generation immunotherapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Faculty of Health Sciences, https://ror.org/01r4q9n85University of Macau, Avenida da Universidade, Taipa, Macao and Zhuhai People's Hospital Centre for Precision Medicine, Zhuhai Clini…
- Department of Cerebrovascular Disease, Center of Intervention Radiology,https://ror.org/01k1x3b35Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of J…
- Department of Biomedical Sciences, Faculty of Health Sciences, https://ror.org/01r4q9n85University of Macau, Avenida de Universidade, Taipa, Macao.
ORCID-Profile: Hang Fai Kwok
Förderung
- Fundo para o Desenvolvimento das Ciências e da Tecnologia
- National Natural Science Foundation of China
Zitieren
APA
Li, Z., Xu, W., & Kwok, H. F. (2026). Targeting CD39 as a Therapeutic for Cancer Immunotherapy. Expert Reviews in Molecular Medicine, 28. https://doi.org/10.1017/erm.2026.10033
Vancouver
Li Z, Xu W, Kwok HF. Targeting CD39 as a Therapeutic for Cancer Immunotherapy. Expert Reviews in Molecular Medicine. 2026;28. doi:10.1017/erm.2026.10033
BibTeX
@article{Li2026,
author = {Li, Zhongliang and Xu, Weiguo and Kwok, Hang Fai},
title = {Targeting CD39 as a Therapeutic for Cancer Immunotherapy},
journal = {Expert Reviews in Molecular Medicine},
year = {2026},
volume = {28},
doi = {10.1017/erm.2026.10033}
}
EUVIMED